Antibody drugs conjugates in non–small cell lung cancer: current status and challenges
ADCs are poised to reshape the therapeutic landscape of NSCLC. Their success will hinge on refining biomarker strategies, managing toxicity, and integrating resistance-mitigating approaches such as bispecific constructs or rational combinations. As research advances, ADCs may become essential components of personalized therapy across a range of molecular and histologic NSCLC subtypes.
Authors
- Jorge Gómez (ORCID: https://orcid.org/0000-0001-6859-363X)
- May‐Lucie Meyer (ORCID: https://orcid.org/0000-0003-2091-9578)
- Kenneth Angelino
- Fred R. Hirsch (ORCID: https://orcid.org/0000-0002-6885-1894)
- Triparna Sen
- Arjun Syal
- Noah Osei
Institutions
- Mount Sinai Hospital (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- Centre Hospitalier Universitaire Vaudois (CH)
- Tisch Hospital (US)
- The Ohio State University (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-10-04
- DOI
- https://doi.org/10.1093/oncolo/oyaf331
- Citations
- 3
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 4.56